Recently, the use of Csn-B, an NR4A1 ligand, has been shown to ameliorate disease burden in a murine serum transfer-induced arthritis (STIA) model, in a collagen-induced (CIA) model and in a rat model of OA (82, 95, 103). This evidence concerns the gene NR4A1 and arthritic joint disease.